InvestorsHub Logo
Followers 7
Posts 319
Boards Moderated 0
Alias Born 01/10/2015

Re: ducruacuteo11 post# 6816

Friday, 02/27/2015 1:26:17 PM

Friday, February 27, 2015 1:26:17 PM

Post# of 43714


CEL-SCI (NYSE: CVM) is the most undervalued Phase lll biotech in America.



CEL-SCI (NYSE: CVM) is the most undervalued Phase lll biotech in America. This turnaround aims to enroll 880 head and neck cancer patients in over 100 sites in at least 21 countries before yearend. Success in this global Phase III trial of its lead immunotherapy drug regime Multikine could be rewarded with a one day stock jump of $ billions. Other tantalizing possibilities exist for HPV and rheumatoid arthritis. Dreamer CEO Geert Kersten and his outstanding team are building a keeper.



http://archive.constantcontact.com/fs141/1101855435216/archive/1120223807599.html

credit Ducruacuteo11 for article find
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CVM News